318 related articles for article (PubMed ID: 36140723)
1. The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets.
Yang G; Lu T; Weisenberger DJ; Liang G
Genes (Basel); 2022 Aug; 13(9):. PubMed ID: 36140723
[TBL] [Abstract][Full Text] [Related]
2. Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
Pezo RC; Chen TW; Berman HK; Mulligan AM; Razak AA; Siu LL; Cescon DW; Amir E; Elser C; Warr DG; Sridhar SS; Yu C; Wang L; Stockley TL; Kamel-Reid S; Bedard PL
Breast Cancer Res Treat; 2018 Feb; 168(1):159-168. PubMed ID: 29177603
[TBL] [Abstract][Full Text] [Related]
3. Genomic Alteration in Metastatic Breast Cancer and Its Treatment.
Li A; Schleicher SM; Andre F; Mitri ZI
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-14. PubMed ID: 32213086
[TBL] [Abstract][Full Text] [Related]
4. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
5. The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.
De Mattos-Arruda L; Sammut SJ; Ross EM; Bashford-Rogers R; Greenstein E; Markus H; Morganella S; Teng Y; Maruvka Y; Pereira B; Rueda OM; Chin SF; Contente-Cuomo T; Mayor R; Arias A; Ali HR; Cope W; Tiezzi D; Dariush A; Dias Amarante T; Reshef D; Ciriaco N; Martinez-Saez E; Peg V; Ramon Y Cajal S; Cortes J; Vassiliou G; Getz G; Nik-Zainal S; Murtaza M; Friedman N; Markowetz F; Seoane J; Caldas C
Cell Rep; 2019 May; 27(9):2690-2708.e10. PubMed ID: 31141692
[TBL] [Abstract][Full Text] [Related]
6. Therapeutics targeting the metastatic breast cancer bone microenvironment.
Ihle CL; Wright-Hobart SJ; Owens P
Pharmacol Ther; 2022 Nov; 239():108280. PubMed ID: 36116682
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics in Metastatic Breast Cancer: Its Regulation and Implications in Diagnosis, Prognosis and Therapeutics.
Wu YS; Lee ZY; Chuah LH; Mai CW; Ngai SC
Curr Cancer Drug Targets; 2019; 19(2):82-100. PubMed ID: 29714144
[TBL] [Abstract][Full Text] [Related]
9. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases.
Wu JM; Fackler MJ; Halushka MK; Molavi DW; Taylor ME; Teo WW; Griffin C; Fetting J; Davidson NE; De Marzo AM; Hicks JL; Chitale D; Ladanyi M; Sukumar S; Argani P
Clin Cancer Res; 2008 Apr; 14(7):1938-46. PubMed ID: 18381931
[TBL] [Abstract][Full Text] [Related]
11. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
[TBL] [Abstract][Full Text] [Related]
12. The genomic landscape of breast cancer brain metastases: a systematic review.
Morgan AJ; Giannoudis A; Palmieri C
Lancet Oncol; 2021 Jan; 22(1):e7-e17. PubMed ID: 33387511
[TBL] [Abstract][Full Text] [Related]
13. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer and metastasis: on the way toward individualized therapy.
Trapé AP; Gonzalez-Angulo AM
Cancer Genomics Proteomics; 2012; 9(5):297-310. PubMed ID: 22990109
[TBL] [Abstract][Full Text] [Related]
15. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer.
Lin NU; Thomssen C; Cardoso F; Cameron D; Cufer T; Fallowfield L; Francis PA; Kyriakides S; Pagani O; Senkus E; Costa A; Winer EP;
Breast; 2013 Jun; 22(3):203-10. PubMed ID: 23601761
[TBL] [Abstract][Full Text] [Related]
16. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
Richard F; Majjaj S; Venet D; Rothé F; Pingitore J; Boeckx B; Marchio C; Clatot F; Bertucci F; Mariani O; Galant C; Eynden GVD; Salgado R; Biganzoli E; Lambrechts D; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C; Desmedt C
Clin Cancer Res; 2020 Dec; 26(23):6254-6265. PubMed ID: 32943456
[TBL] [Abstract][Full Text] [Related]
18. miRNA profile obtained by next‑generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments.
Martinez-Gutierrez AD; Catalan OM; Vázquez-Romo R; Porras Reyes FI; Alvarado-Miranda A; Lara Medina F; Bargallo-Rocha JE; Orozco Moreno LT; Cantú De León D; Herrera LA; López-Camarillo C; Pérez-Plasencia C; Campos-Parra AD
Int J Mol Med; 2019 Oct; 44(4):1267-1280. PubMed ID: 31364724
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations.
Ross DS; Pareja F
Clin Lab Med; 2024 Jun; 44(2):255-275. PubMed ID: 38821644
[TBL] [Abstract][Full Text] [Related]
20. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
